Article Details

Xeris Pharmaceuticals (NASDAQ:XERS) Upgraded to "Buy" by Zacks Investment Research

Retrieved on: 2020-11-26 17:48:45

Tags for this article:

Click the tags to see associated articles and topics

Xeris Pharmaceuticals (NASDAQ:XERS) Upgraded to "Buy" by Zacks Investment Research. View article details on hiswai:

Excerpt

Charles Schwab <b>Investment</b> Management Inc. now owns 107,496 shares of the company's stock worth $638,000 after acquiring an additional 14,950 ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo